Advertisement

Topics

Adalimumab and infliximab biosimilars from Sandoz accepted for review by EMA

05:01 EDT 30 Jun 2017 | Generics and Biosimilars Initiative

Sandoz, the generics division of Novartis, announced on 31 May 2017 that the regulatory submissions for its proposed adalimumab (GP2017) and infliximab (PF‑06438179) biosimilars had been accepted by the European Medicines Agency (EMA).

Original Article: Adalimumab and infliximab biosimilars from Sandoz accepted for review by EMA

NEXT ARTICLE

More From BioPortfolio on "Adalimumab and infliximab biosimilars from Sandoz accepted for review by EMA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...